Obulytix, a spin-off from UGent and KU Leuven, sees proteins from bactericidal viruses as the solution to the growing problem of antibiotic resistance. ‘With this, we can make an optimal antibiotic against any possible bacterial infectious disease.’

‘The antibiotic resistance crisis is getting worse and worse’, sighs Yves Briers, CEO and co-founder of Ghent based Obulytix. ‘There used to be multi-drug resistance, where bacteria were resistant to a few classes of antibiotics. This number has increased. And now there are the first pan-drug resistant strains. This means that no antibiotic works against these bacteria.’